Polyps are small gray, semitranslucent, grapelike masses. When they grow inside the nasal passages they can create an obstruction that makes it difficult to smell and breathe through the nose. Polyps ...
Nasal polyps are common, affecting up to 4% of the general population, and can affect quality of life, but are usually benign. However, a new study suggests that when they occur in older patients (≥ ...
The FDA has approved Tezspire (tezepelumab-ekko), a biologic therapy by Amgen and AstraZeneca, as an add-on maintenance ...
Please provide your email address to receive an email when new articles are posted on . PCPs typically assess nasal congestion and runny nose by shining a light in the nasal passage or using an ...
A few months after licensing its drug delivery platform for migraine treatment to Avanir Pharmaceuticals, OptiNose is shifting its focus to nasal polyposis. The condition affects up to 4 percent of ...
AstraZeneca and Amgen's Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy with ...
-- American Journal of Rhinology & Allergy Article Highlights Company's Bi-directional Delivery Technology for Chronic Rhinosinusitis with Nasal Polyps; Technology Significantly and Progressively ...
Nasal polyps can be a persistent issue for individuals suffering from chronic sinusitis, allergies, or fungal infections, often leading to breathing difficulties and discomfort. When medications and ...
POPS is a breakthrough in the assessment of chronic rhinosinusitis with nasal polyposis. It allows us to better document the severity of polyps in the postoperative sinus cavity.” — Thomas S. Higgins, ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback